Navigation Links
Favrille in Medical News

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...g Agreement with Seattle Genetics II-51 Celgene Agrees to Acquisition of Pharmion II-51 PerkinElmer Plans Acquisition of ViaCell II-51 favrille Announces Acquisition of Monoclonal Antibody Range from Diversa II-52 Johnson & Johnson Secures Contract worth US$112 Million II-52 Bi...

MyMedicalRecords, Inc. and Favrille, Inc. Close Merger

... needs." "We believe that the combination of favrille and MMR offers our creditors and stockholders the ..." Merger Overview For legal purposes, favrille is acquiring MMR although the combination will be ...ses. As consideration in the business combination, favrille has issued (or reserved for issuance) 92,599,196 s...

Favrille and MyMedicalRecords.com, Inc. Announce Merger Agreement

...21LOGO ) "We believe that the proposed merger of favrille and MMR is consistent with our objective of offeri...ere in the world. We believe this transaction with favrille will give MMR broader access to the investment com...saction Under the terms of the merger agreement, favrille will acquire all of the capital stock of MMR, in a...

Favrille Announces Listing on OTC Bulletin Board

...le's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting

.... About the Phase 3 Clinical Trial of Specifid favrille initiated a pivotal, double-blind, placebo control... from the U.S. Food and Drug Administration (FDA). favrille has also received Fast Track designation from the ...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...
Favrille in Medical Technology

Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June

...mation and prepare for the analysis and unblinding of the trial in June." favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registra...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...Based in part on the guidance provided by the DMB, favrille has determined April 2008 to be the appropriate ti...se 3 trial." Third Quarter 2007 Financial Review favrille also reported its financial results for the third ...f 2008." Conference Call and Webcast Information favrille management will host a conference call today to di...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

...ient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId followi...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

...ient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId followi...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...
Favrille in Biological Technology

Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger

...521LOGO ) "We are pleased to announce that favrille creditors holding more than 85% of the dollar valu...merger is subject to customary closing conditions, favrille meeting certain minimum cash requirements as of cl...and Where to Find It On November 13, 2008, favrille filed a Current Report on Form 8-K with the SEC th...

Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction

...on-binding term sheet for a reverse merger whereby favrille would acquire all of the capital stock of a privat...f MMR would own approximately 64% of the equity of favrille on a fully diluted basis. The existing equity holders of favrille would own approximately 29% of the Company. Approx...

Favrille Announces Receipt of Nasdaq Letters

...w the minimum $1.00 per share requirement and (ii) favrille has not maintained the $5,000,000 minimum market v...y. In accordance with Marketplace Rule 4450(e)(1), favrille has 90 calendar days, or until October 7, 2008, to...e with the minimum $1.00 per share requirement. If favrille does not regain compliance with either of the abov...

Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets

...ll all unneeded fixed assets in the near future. favrille is currently in discussions with its landlord rega... options. The management and board of directors of favrille remain committed to addressing these issues and ma...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...

Favrille Announces Workforce Reduction

...le's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma

...for their support and dedication." About the Phase 3 Registration Trial favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registra...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Reports First Quarter 2008 Financial Results

...the first quarter of 2007. As of March 31, 2008, favrille had cash, cash equivalents and short-term investme...ng options." Phase 3 Registration Trial Update favrille reached the data cutoff date for its Phase 3 regis...trial. Conference Call and Webcast Information favrille management will host a conference call today to di...

Favrille Reports Fourth Quarter and Year End 2007 Financial Results

...e same periods in 2006. As of December 31, 2007, favrille had cash, cash equivalents and short-term investme...rille. Conference Call and Webcast Information favrille management will host a conference call today to di...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...

Favrille Announces $21.1 Million Registered Direct Offering

...cal trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille to Present at BIO InvestorForum

...held at the Palace Hotel in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO ) Ms. Seymour will provide an overview of favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell ...
Other Tags
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... launched a ‘responsive design’ website to inform potential sinus surgery patients about ear, ... The website includes information about a wide variety of ENT issues including hearing ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier provider of ... Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored at the ... for her contribution to the RBMA Coding Subcommittee. , Ms. Mann served ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand Terrace Health Care ... Care Center.” Each year, Medicare ranks care centers around the country in an ... their needs. Grand Terrace prides itself on quality in each of Medicare’s evaluation ...
(Date:6/30/2015)... ... 30, 2015 , ... According to a June 15th report from ... how sensory stimuli can be used to “decrease children’s anxiety and negative responses during ... autism, will compare patient experience in a “typical dental environment” with one that provides ...
Breaking Medicine News(10 mins):Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
Other Contents